Delayed
Hong Kong S.E.
02:00:46 2024-05-16 am EDT
|
5-day change
|
1st Jan Change
|
10.7
HKD
|
-1.65%
|
|
-0.55%
|
-11.87%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,845
|
6,776
|
6,054
|
-
|
-
|
Enterprise Value (EV)
1 |
8,845
|
6,776
|
5,507
|
6,054
|
6,054
|
P/E ratio
|
21.6
x
|
-65.8
x
|
-252
x
|
201
x
|
91.6
x
|
Yield
|
-
|
-
|
33.3%
|
33.6%
|
34.6%
|
Capitalization / Revenue
|
2.35
x
|
7.6
x
|
6.18
x
|
5.56
x
|
4.86
x
|
EV / Revenue
|
2.35
x
|
7.6
x
|
5.62
x
|
5.56
x
|
4.86
x
|
EV / EBITDA
|
14.4
x
|
-
|
33.8
x
|
29.5
x
|
-
|
EV / FCF
|
-49.3
x
|
-
|
46.5
x
|
28.9
x
|
18.5
x
|
FCF Yield
|
-2.03%
|
-
|
2.15%
|
3.46%
|
5.42%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
621,251
|
606,149
|
601,087
|
-
|
-
|
Reference price
2 |
14.24
|
11.18
|
10.07
|
10.07
|
10.07
|
Announcement Date
|
3/30/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3,756
|
891.5
|
979.3
|
1,089
|
1,245
|
EBITDA
1 |
-
|
614.6
|
-
|
163
|
205
|
-
|
EBIT
1 |
-
|
458.6
|
-112.2
|
-7
|
56.5
|
114.5
|
Operating Margin
|
-
|
12.21%
|
-12.58%
|
-0.71%
|
5.19%
|
9.2%
|
Earnings before Tax (EBT)
1 |
-
|
443.4
|
-86.81
|
-28.05
|
38.64
|
80.09
|
Net income
1 |
380.9
|
377.3
|
-102.3
|
-25.31
|
30.56
|
66.62
|
Net margin
|
-
|
10.04%
|
-11.47%
|
-2.58%
|
2.8%
|
5.35%
|
EPS
2 |
38.21
|
0.6600
|
-0.1700
|
-0.0400
|
0.0500
|
0.1100
|
Free Cash Flow
1 |
-
|
-179.5
|
-
|
118.5
|
209.5
|
328
|
FCF margin
|
-
|
-4.78%
|
-
|
12.1%
|
19.23%
|
26.35%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
72.7%
|
102.2%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
685.63%
|
492.33%
|
Dividend per Share
2 |
-
|
-
|
-
|
3.350
|
3.380
|
3.490
|
Announcement Date
|
5/4/22
|
3/30/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
547
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-179
|
-
|
119
|
210
|
328
|
ROE (net income / shareholders' equity)
|
-
|
18.9%
|
-
|
-0.63%
|
1.53%
|
2.4%
|
ROA (Net income/ Total Assets)
|
-
|
10.2%
|
-
|
-0.9%
|
0.95%
|
3%
|
Assets
1 |
-
|
3,681
|
-
|
2,812
|
3,216
|
2,221
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
317
|
-
|
117
|
93.3
|
93.3
|
Capex / Sales
|
-
|
8.44%
|
-
|
11.91%
|
8.57%
|
7.5%
|
Announcement Date
|
5/4/22
|
3/30/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
10.07
CNY Average target price
12.93
CNY Spread / Average Target +28.35% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.87% | 837M | | -15.96% | 8.57B | | +67.50% | 4.3B | | -4.03% | 2.46B | | -42.54% | 2.31B | | -6.49% | 1.93B | | -20.45% | 1.53B | | -41.24% | 1.2B | | +10.26% | 1.14B | | +18.74% | 986M |
Medical & Diagnostic Laboratories
|